Supporting Information for

Sulfolipid-1 Biosynthesis Restricts *Mycobacterium tuberculosis* **Growth in Human Macrophages**

 $Sarah A. Gilmore[*], Michael W. Schelle[†], Cynthia M. Holsclaw[¶], Clifton D. Leigh[†], Madhulika$ *Jain , Jeffery S. Cox , Julie A. Leary¶,§, and Carolyn R. Bertozzi*, †, ‡,1*

Departments of Chemistry[†] and Molecular and Cell Biology^{*}, Howard Hughes Medical

Institute[‡], University of California, Berkeley, CA 94720; Section of Molecular and Cell Biology[¶]

and Department of Chemistry[§], University of California, Davis, CA 95616; and Department of

Microbiology and Immunology , University of California, San Francisco, CA 94143.

¹To whom correspondence may be addressed: University of California, B84 Hildebrand Hall,

#1460, Berkeley, CA 94720. Tel: (510) 643-1682. Fax: (510) 643-2628. E-mail:

crb@berkeley.edu

Supplemental Figure Legends

Figure S1. Model of SL-1 biosynthesis

Free trehalose is sulfated by Stf0 to form T2S. PapA2 then acylates the 2'-position of T2S to form SL659. Pks2 synthesizes a (hydroxy)phthioceranic acid which is transferred directly by PapA1 onto SL_{659} to form SL_{1278} . The diacylated SL_{1278} is then transferred by the putative lipid transporter MmpL8 to the exterior of the cell wall where the two final acylation reactions occur to yield fully elaborated SL-1.

Figure S2. MALDI-TOF MS of purified SL-1 SL-1 was enriched by anion-exchange chromatography and further purified via HPLC silica column. SL-1 is observed as a collection of lipoforms that vary in the lengths of their acyl groups $(\pm 14 \text{ mass units}).$

Figure S3. SL-1 does not modulate pro-inflammatory cytokine production *in vitro*

hiDCs, human primary macrophages, the human monocyte THP-1 cell line, or the murine macrophage RAW264.7 cell line were cultured with SL-1, SL-A, or LPS. Levels of TNF produced by each cell type in response to the indicated stimulus were evaluated by ELISA. Data are representative of at least two independent experiments performed in triplicate, with human cells derived from different donors where appropriate. Error bars represent the standard deviation from the mean.

Figure S4. Qualitative MS analysis of *stf0* mutant for T2S and PDIM

(a) Disruption of *stf0* abolishes trehalose-2-sulfate (T2S) production. FT-ICR MS of chloroform: methanol extracts of WT, ∆*stf0*, and ∆*stf0* + p*stf0* strains verify loss of T2S (m/z=421.06), as denoted by an asterisk, from ∆*stf0*. The other species observed in ∆*stf0* and the ∆*stf0* + p*stf0* strains is a phosphorylated disaccharide that is not visible in WT samples due to ion suppression that occurs when analyzing complex lipid extracts. (b) PDIM synthesis is intact in the ∆*stf0* mutant. FT-ICR analysis of surface-extractable lipids reveals that PDIM retains the same average m/z= 1402 in the ∆*stf0* mutant as compared to WT.

Figure S5. ∆*stf0* displays no *in vitro* growth defects

The *in vitro* growth rates of ∆*stf0*, WT, and ∆*stf0* + p*stf0* Mtb were approximated by measuring their optical density at 600 nm over time. Data are representative of three independent experiments.

Figure S6. ∆*papA2* is more resistant to LL-37 compared to WT Mtb.

The indicated strains of Mtb were exposed to increasing concentrations (0, 6.5, and 65 µg/mL) of LL-37. After 3 days, Mtb viability was measured by plating bacteria on solid agar to enumerate cfu counts. Data are representative three biological replicates. Error bars correspond to the means (± s.d.). *, P=0.329 (not significant) for the comparison of ∆*papA2* versus WT; **, P=0.018 for the comparison of ∆*papA2* versus WT.

Figure S7. Stf0 displays no trafficking defects compared to WT *in vivo* Liver (a) and spleen (b) cfu counts for BALB/c mice infected via aerosol with WT or ∆*stf0* Mtb. Each data point represents the average cfu count from 4-5 mice, and error bars indicate the standard deviation from the mean.

Table Legend

Table S1. Top 50 most highly upregulated microarray gene identities. Identities of the 50 most highly up regulated, statistically significant (p<0.02) genes induced in hiDCs by SL-1, SL-A, or P3K as represented in Figure 2.

Supplemental Figures

Figure S1

Figure S2

Figure S3

Figure S4.

Figure S5.

Figure S6

Figure S7

Supplemental Table

Supplemental Materials and Methods

Determination of Mtb growth rates *in vitro*. Mtb was grown to late log phase, washed twice in PBS and pelleted by centrifugation at low speed to remove clumps. The $OD₆₀₀$ was adjusted to 0.02 in 50 mL of complete 7H9 media and the growth of each strain was approximated by measuring the OD_{600} every 24-48 hours.

Generation of human primary macrophages and immature dendritic cells. Total human peripheral blood mononuclear cells (PBMCs) were obtained as buffy coats from the American Red Cross, Oakland, CA. PBMCs were prepared by sedimentation of erythrocytes with Dextran T500 and separation over a Ficoll-Hypaque gradient. Total monocytes were obtained by negative isolation using Dynal Monocyte MyPure Negative Isolation Kit (Invitrogen) and cultured in AIM-V media supplemented with 1% human AB serum and 20-50 ng mL⁻¹ of M-CSF to generate macrophages or 500U mL⁻¹ IL-4 and 1000U mL⁻¹ GM-CSF to generate hiDCs. Media was replaced on days 2 and 4 of culture to replenish growth factors.

SL-1 purification. Approximately 5 g of -irradiated Mtb H37Rv whole cells (Colorado State University) were extracted in 100mL chloroform: methanol (1:1, v/v) at room temperature for 2 h. The organic layer was filtered 3 times by vacuum filtration, concentrated, and further partitioned between chloroform and water to constitute the total Mtb lipid extract. 40 mg of lipid extract was resuspended in chloroform/methanol (4:1, v/v) and passed over an anion-exchange column (AG4-X4 resin, 100−200 mesh, biotechnology grade, free-base form, Bio-RAD) that was pre-charged with chloroform/methanol/acetic acid (400:100:0.6, v/v). The column was washed with chloroform/methanol (4:1, v/v) and binders were eluted using a gradient of 2−5 mM triethylamine in chloroform/methanol (4:1, v/v). Fractions were mixed (1:1, v/v) with matrix solution $(10 \text{ mg ml}^{-1} 2-[4-Hydroxyphenylazo]$ benzoic acid) and analyzed by matrix assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS, Applied Biosystems Voyager DE Pro). Fractions containing SL-1 were pooled and further purified by HPLC on a silica column (Varian Microsorb 100, particle size 5µm). Prior to injection, the column was first equilibrated in chloroform/methanol (98:2, v/v) and SL-1 was eluted with a 2- 27% methanol gradient over 30 minutes. Fractions were collected and analyzed for purity by MALDI as well as by TLC using a $60:12:1$ (v/v) chloroform: methanol: water solvent system.

Stimulation of leukocytes with SL-1, SL-A, or LPS. 4 x 10⁵ hiDCs, human primary macrophages, THP-1, or RAW264.7 cells were treated with 20μ g mL⁻¹ SL-1, 20μ g mL⁻¹ SL-A that had been dissolved in petroleum ether and allowed to evaporate off the bottom of a cell culture dish or $20ng \, mL^{-1} LPS$ as indicated. After 24 hours, the amount of TNF elicited by each cell type was analyzed by ELISA according to the manufacturer's recommendations (BD Bioscience).

∆*papA2* **Antimicrobial Peptide Susceptibility**

The construction of ∆*papA2* in the Erdman strain of Mtb was reported in (1). For complementation of ∆*papA2*, the *papA2* gene was cloned from Mtb into the integrating mycobacterial expression vector pMV306 under the control of its putative endogenous promoter (2). This plasmid was electroporated into ∆*papA2*, and transformants were selected on kanamycin-containing plates. Sensitivity of Mtb to antimicrobial peptides was assayed as previously described (3). Briefly, Mtb was grown to late-log phase, washed in PBS, and pelleted by centrifugation at low speed to remove clumps. Cells $(2x10⁶)$ of each strain were exposed to the indicated concentration of LL-37 (AnaSpec) dissolved in RPMI: water (1:4, v/v) at 37 °C. After three days, bacteria were plated on solid agar to enumerate the number of viable bacteria by cfu counts.

Microarray Preparation, Array Hybridizations, and Analysis

Microarray sample preparation, labeling, and array hybridizations were performed according to standard protocols from the UCSF Shared Microarray Core Facilities and Agilent Technologies (http://www.arrays.ucsf.edu and http://www.agilent.com). RNA was amplified and labeled with Cy3-CTP using the Agilent low RNA input fluorescent linear amplification kits following the manufacturer's protocol. Labeled cRNA was assessed using the Nandrop ND-100 (Nanodrop Technologies, Inc.), and equal amounts of Cy3 labeled target were hybridized to Agilent whole human genome 4x44K arrays. Arrays were scanned using the Agilent microarray scanner and raw signal intensities were extracted with Feature Extraction v9.1 software. The dataset was normalized using the *quantile* normalization method that is proposed by Bolstad et al. (4). No background subtraction was performed, and the median feature pixel intensity was used as the raw signal before normalization. A small number of probes (245) have replicate spots, and these were summarized by taking the median intensity. A linear model was fit to the comparison to estimate the mean M values and calculated moderated t-statistic, B statistic, false discovery rate and p-value for each gene for the comparison of interest. All procedures were carried out using functions in the R package *limma in Bioconductor* (5,6).

Supplemental References

1.Kumar, P., Schelle, M. W., Jain, M., Lin, F. L., Petzold, C. J., Leavell, M. D., Leary, J. A., Cox, J. S., and Bertozzi, C. R. (2007) PapA1 and PapA2 are acyltransferases essential for the biosynthesis of the Mycobacterium tuberculosis virulence factor sulfolipid-1, *Proc Natl Acad Sci U S A 104*, 11221-11226.

2.Stover, C. K., de la Cruz, V. F., Fuerst, T. R., Burlein, J. E., Benson, L. A., Bennett, L. T., Bansal, G. P., Young, J. F., Lee, M. H., Hatfull, G. F., and et al. (1991) New use of BCG for recombinant vaccines, *Nature 351*, 456-460.

3. Liu, P. T., Stenger, S., Li, H., Wenzel, L., Tan, B. H., Krutzik, S. R., Ochoa, M. T., Schauber, J., Wu, K., Meinken, C., Kamen, D. L., Wagner, M., Bals, R., Steinmeyer, A., Zugel, U., Gallo, R. L., Eisenberg, D., Hewison, M., Hollis, B. W., Adams, J. S., Bloom, B. R., and Modlin, R. L. (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response, *Science 311*, 1770-1773

4. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. *Bioinformatics* 19:185-193.

5. Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., Hornik, K., Hothorn, T., Huber, W., Iacus, S., Irizarry, R., Leisch, F., Li, C., Maechler, M., Rossini, A. J., Sawitzki, G., Smith, C., Smyth, G., Tierney, L., Yang, J. Y., and Zhang, J. (2004) Bioconductor: open software development for computational biology and bioinformatics, *Genome biology 5*, R80.

6. Smyth, G. K. (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments, *Statistical applications in genetics and molecular biology 3*, Article3.